

Zongli Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6941735/publications.pdf>

Version: 2024-02-01

21
papers

478
citations

759233

12
h-index

839539

18
g-index

23
all docs

23
docs citations

23
times ranked

444
citing authors

#	ARTICLE	IF	CITATIONS
1	Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway. <i>EBioMedicine</i> , 2019, 47, 142-155.	6.1	64
2	Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression. <i>Oncotarget</i> , 2017, 8, 4888-4900.	1.8	57
3	Transcription factor 7 promotes the progression of perihilar cholangiocarcinoma by inducing the transcription of c-Myc and FOS-like antigen 1. <i>EBioMedicine</i> , 2019, 45, 181-191.	6.1	48
4	WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1 α accumulation in Myc-dependent and independent pathways. <i>Molecular Therapy</i> , 2021, 29, 2134-2150.	8.2	44
5	FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis. <i>Oncogene</i> , 2021, 40, 4941-4953.	5.9	40
6	HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 86.	8.6	33
7	The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent. <i>Biochemical and Biophysical Research Communications</i> , 2016, 476, 260-266.	2.1	27
8	Norcantharidin Suppresses Colon Cancer Cell Epithelial-Mesenchymal Transition by Inhibiting the β 1-6-ERK-Ets1 Signaling Pathway. <i>Scientific Reports</i> , 2016, 6, 20500.	3.3	27
9	The Smad4-MYO18A-PP1A complex regulates β -catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma. <i>Cell Death and Differentiation</i> , 2022, 29, 818-831.	11.2	26
10	Sprouty4 correlates with favorable prognosis in perihilar cholangiocarcinoma by blocking the FGFR-ERK signaling pathway and arresting the cell cycle. <i>EBioMedicine</i> , 2019, 50, 166-177.	6.1	20
11	Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway. <i>Oncogene</i> , 2022, 41, 2885-2896.	5.9	20
12	High mobility group box 1/toll-like receptor 4/myeloid differentiation factor 88 signaling promotes progression of gastric cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769431.	1.8	18
13	Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression. <i>Cell Death and Disease</i> , 2021, 12, 1158.	6.3	15
14	Clinicopathological Features and Treatment Outcomes of Solid Pseudopapillary Neoplasms of the Pancreas: A 10-Year Case Series from a Single Center. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2019, 29, 600-607.	1.0	14
15	Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study. <i>BMC Cancer</i> , 2016, 16, 424.	2.6	12
16	Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 777617.	2.8	5
17	Combined Endovascular Embolization and Open Surgery for Splenic Artery Aneurysm with Arteriovenous Fistula. <i>Annals of Vascular Surgery</i> , 2016, 30, 311.e1-311.e4.	0.9	4
18	PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109583.	5.6	4

#	ARTICLE	IF	CITATIONS
19	Repeated Hepatolithiasis and Unknown Mass inÂCholangiography. <i>Gastroenterology</i> , 2016, 151, e9-e11.	1.3	0
20	Exosome-Mediated Bmi1 Promotes Cholangiocarcinoma Growth and Metastasis Through the Differential Regulation of miR-320b and miR-27b-3p. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
21	Abstract CT546: A phase 2, multicenter study to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in patients with HCC at high risk of recurrence after curative resection. <i>Cancer Research</i> , 2022, 82, CT546-CT546.	0.9	0